MAKEUP MANUFACTURING BUSINESS PLAN

I. Executive Summary

Company Description

Pacific Form Labs—named for Los Angeles’ Pacific coastline and the lab-based precision of our work—launched in 2026 as a US-based manufacturing partner for independent beauty brands. We operate in the cosmetics and skincare manufacturing sector, providing end-to-end services: custom formulation, ingredient sourcing, regulatory documentation, and scalable production. Our facility is FDA-registered and GMP-compliant, built to meet the Modernization of Cosmetics Regulation Act standards. One clear line: we turn creative concepts into market-ready color cosmetics and skincare at domestic scale.

We run formulation kitchens, pilot lines, quality control labs, and finished-goods production so brands avoid offshore delays and compliance risk. What sets us apart is fast iteration cycles, stringent QA, and US-based supply chains that shorten lead times and protect brand reputation. We target indie and DTC beauty founders seeking premium domestic manufacture in the US mass‑to‑prestige segment. Short-term goal: onboard 12 recurring brand clients and reach $3M revenue by end-2027. Long-term goal: become the West Coast contract manufacturer of choice and hit $25M revenue with 25% gross margin by 2030. One clear line: domestic quality, agile delivery, and regulatory readiness drive our growth.

Problem

Independent U.S. beauty founders face prohibitive barriers to entry because traditional manufacturers require high minimum order quantities, creating large upfront capital needs and high inventory risk. Supply chains are fragmented—formulation, production, and packaging come from different providers—raising lead times, coordination costs, and reducing agility to follow fast-moving social media trends. Domestic manufacturing capacity is scarce, pushing many brands overseas and increasing lead time, quality variability, and compliance risk.

The Modernization of Cosmetics Regulation Act of 2022 increased regulatory complexity and liability for small brands that lack in-house compliance expertise, further raising costs and time to market and increasing exposure to regulatory penalties. One-liner: Small beauty brands can’t afford large MOQs, fragmented suppliers, or rising regulatory burden, leaving a clear gap for agile, low-volume, compliant domestic manufacturing.

We launched in 2026 as a Los Angeles–based, FDA-registered, GMP-compliant manufacturing partner offering end-to-end services—custom formulation, ingredient sourcing, and scalable production—for color cosmetics and skincare to address this gap.

Solution

Emerging beauty brands face high minimums, complex international supply chains, new US regulatory hurdles, and forced over-ordering that creates financial risk. We provide a flexible, US-based manufacturing partner that removes those barriers, offering compliant formulation, vetted domestic ingredients, low minimum runs, and integrated packaging so brands can launch fast and scale without excess inventory.

One line: a single US vendor for compliant formulation, low-MOQ production, and retail-ready delivery.

Mission Statement

Our mission is to empower the next generation of beauty innovators by providing high-quality manufacturing and strategic support that scales creative concepts into world-class products. We are committed to revitalizing US cosmetic manufacturing with agility, transparency, and clean compliant formulations, lowering barriers to professional production while driving quality, safety, and economic growth.

Key Success Factors

Success rests on low minimum orders paired with industrial-grade quality, regulatory expertise, skilled leadership, strategic location, and sound finance.

• Low minimum order quantities with industrial-grade quality to serve indie and legacy brands.
• Lead Cosmetic Chemist driving formulation quality, speed to market, and technical credibility.
• US FDA-compliant facility ensuring regulatory alignment and customer trust.
• Strategic location in a major beauty hub to attract talent and stay close to key suppliers.
• Regulatory and financial strength including MCRA expertise and a path to $2,056,000 EBITDA by year five.

Financial Summary

Brief financial snapshot for the Executive Summary: first-year revenue, path to breakeven, EBITDA trajectory, and key return metrics.

Financial requirements: minimum cash buffer of $747,000 is required to reach the breakeven target in Jan-2027 (13 months); anticipated payback period is 31 months; reported IRR 0.05% and ROE 4.69%.

Overall outlook: revenue scales quickly and EBITDA turns positive in year two, supporting a solid path to sustained profitability.

Funding Requirements

We seek 1,237,000 USD to fund a Los Angeles facility build-out, equipment, core hires and a 13‑month operating buffer to reach breakeven in January 2027 with projected 2026 revenue of 1,699,000 USD, EBITDA rising from -35,000 USD in year one to 2,056,000 USD by year five, IRR 0.05%, ROE 4.69%, and a production plan scaling to 145,000 units annually by 2030.